With the introduction of a subcutaneous formulation, ENTYVIO has expanded patient convenience and global accessibility. Continued growth is supported by rising IBD prevalence and ongoing geographic ...

Merck & Co. Inc. (NYSE: MRK) is rewarding its shareholders once again with a quarterly dividend of $0.81 per share, payable ...

Merck & Co has a lower P/E than the aggregate P/E of 26.97 of the Pharmaceuticals industry. Ideally, one might believe that ...

Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

MSD obtains a Non-Exclusive License for Cyprumed’s delivery technology to develop oral peptide therapeuticsCyprumed will be eligible to receive ...

We recently published a list of the 11 Cheap NYSE Stocks to Invest in According to Hedge Funds. In this article, we are going ...

Merck is holding strong among billionaire favorites, despite the broader healthcare sector dodging investor affection like a ...

The "Keytruda Market Size, Share & Trends Analysis Report By Application (Lung Cancer, Breast Cancer, Melanoma, Hodgkin Lymphoma), By Payer (Commercial/Private, Public), By Distribution Channel, By ...

Trump on Tuesday said his administration will be announcing a “major” tariff on pharmaceuticals “very shortly.” ...

Semarion's SemaCyte® technology transforms adherent cell assays, enabling faster, automated workflows that enhance ...